Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2005, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. In addition, sales of Amgen's products are affected by the availability of reimbursement and the reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers, and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products. In addition, Amgen competes with other companies with respect to some of Amgen's marketed products as well as for the discovery and development of new products. Amgen believes that some of the newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen products may compete against products that have lower prices, established reimbursement, superi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
(Date:5/21/2013)... N.C. and HENDERSONVILLE, N.C. ... Medicare bidding procurement program for home medical equipment ... North Carolina to lay off employees ... the quality of service and products received by Medicare ... Under the defective and dangerous program, the Centers ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... Dec. 22 Mylan Inc. (Nasdaq: MYL ) today ... approval from the U.S. Food and Drug Administration (FDA) under ... New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 ... form were developed by Matrix for use in treating pediatric ...
... , , , , ... announced that it has entered into an agreement with Laboratoires ... lipase. , DSM has successfully completed process development and commenced ... and Phase I clinical needs. DSM BioSolutions manufactures the lipase ...
Cached Medicine Technology:Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games will bring more ... Columbia. This state-level event takes place May 30-June 2, on ... and at Hickman High School and Town & Country Lanes. ... 7:30 p.m. Friday, May 30 with the Opening Ceremony. The ... of Athletes, the culmination of the statewide Law Enforcement Torch ...
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... May 21, 2013 Children using ... Sophono, Inc., experience audiological results comparable to the ... many fewer complications, according to a new study. ... that Sophono’s abutment-free technology performs just as well ... with many fewer complications,” says Jim Kasic, president ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
(Date:5/21/2013)... Positively charged gold nanoparticles are usually toxic to ... nanoparticle toxicity. Mayo Clinic researchers found out why, ... against ovarian cancer cells. The discovery is detailed ... Journal of Biological Chemistry ., "This study identifies ... by preventing the cell death or apoptosis which ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2
... Healing Ministry, who is a self-proclaimed AIDS healer, was ... of Sh1.6 million.// The money was obtained by telling ... through prayers. ,The Nairobi Principal Magistrate, Margaret ... officer, Patrick Nyale said that many more people were ...
... tobacco by youngsters will cost their dear lives and India ... a year, which will greatly affect the country’s economic growth//, ... tobacco users and more than 900,000 people succumb to tobacco-related ... number of youths falling prey to the addiction. ...
... to treat diabetic nerve damage has shown promising results. A ... when injected into the system, it was found to trigger ... and feet – diabetic neuropathy. ,The positive ... further evidence that the research could lead to a new ...
... falling standards of cleanliness despite Government promises to clean ... in 2002, only 52 percent reported about clean wards. ... very clean, but only 46 percent this year. Contradicting ... levels of general satisfaction with the health service. ...
... to a report by the public services watchdog, the hospitals ... of patients with potentially// fatal condition known as ‘Deep vein ... usually in the leg. ,An enquiry that was ... died from DVT, found that the failure to diagnose the ...
... reputation to disagree with any other form of treatment. But to ... to have a better life//. ,A resident artist much ... Scotland.,The lady in question is Susan Grant, a graduate of the ... coming by the Scottish Arts Council. ,It is one ...
Cached Medicine News:Health News:Tobacco Consumption By Youths Will Hamper India’s Economic Growt 2Health News:New Gene Therapy Treats Diabetic Neuropathy 2Health News:Hospitals In Scotland Not Diagnosing DVT Properly 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0454....
For use with catalog #0454....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Medicine Products: